RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery.
Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue.
Drugs used in chemotherapy, such as paclitaxel, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer.
Condition or disease
- Stage II Non-Small Cell Lung Cancer AJCC v7
- Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
- Stage III Non-Small Cell Lung Cancer AJCC v7
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Drug: Carboplatin
- Drug: Cisplatin
- Biological: Durvalumab
- Drug: Etoposide
- Drug: Paclitaxel
- Drug: Pemetrexed Disodium
- Radiation: Photon Beam Radiation Therapy
- Radiation: Proton Beam Radiation Therapy
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
For questions about study details and eligibility criteria, please contact the study team:
Keywordsplatinum-based chemotherapy, lung cancer, radiotherapy, proton therapy
Principal InvestigatorBradford Hoppe, M.D.
Sponsoring GroupDepartment of Radiation Oncology
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.